Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C1 | P04150 | 5/20 | 0.35 |
| ▸ | NR3C2 | P08235 | 2/20 | 0.33 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.31 |
| ▸ | HPRT1 | P00492 | 1/20 | 0.31 |
| ▸ | IDO1 | P14902 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27117088 | 0.79 | CYP1A2 (0.43) | NR3C1NR3C2HPRT1IDO1 | |
| SCHEMBL22967811 | 0.74 | NR3C1 (0.39) | NR3C1NR3C2TRPV1 | |
| SCHEMBL18428139 | 0.70 | CYP1A2 (0.38) | NR3C1NR3C2IDO1 | |
| SCHEMBL22967807 | 0.70 | CYP1A2 (0.43) | NR3C1NR3C2IDO1 | |
| SCHEMBL19440734 | 0.69 | PIM1 (0.32) | — | |
| SCHEMBL19700542 | 0.69 | MMP1 (0.38) | NR3C1 | |
| SCHEMBL23178987 | 0.68 | CA2 (0.40) | HPRT1 | |
| SCHEMBL1527266 | 0.67 | CYP1A2 (0.46) | NR3C1 | |
| SCHEMBL21413819 | 0.66 | ESR1 (0.33) | — | |
| SCHEMBL20596846 | 0.65 | NR3C1 (0.34) | NR3C1NR3C2HPRT1IDO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11566016-B2 | MAP kinase modulators and uses thereof | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2023-01-31 | — | — | US | disclosed |
| US-20220009905-A1 | MAP KINASE MODULATORS AND USES THEREOF | NORTHWESTERN UNIVERSITY | 2022-01-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11566016-B2 | MAP kinase modulators and uses thereof | MAPK1, MAP3K1, MAP3K2 | NR3C1 2523/4885NR3C2 3345/4885TRPV1 3146/4885 |
| US-20220009905-A1 | MAP KINASE MODULATORS AND USES THEREOF | MAPK1, MAP3K1, MAP3K2 | NR3C1 2523/4885NR3C2 3345/4885TRPV1 3146/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.